METHOD OF TREATING PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY DOUBLE REFRACTORINESS WITH HELP OF NATURAL KILLER-CELL ADAPTIVE IMMUNOTHERAPY Russian patent published in 2025 - IPC A61K35/51 A61K31/675 A61P35/02 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology, and can be used in treating patients with multiple myeloma complicated by double refractoriness. Method involves weekly intravenous transfusion of donor concentrate of haematopoietic stem cells (HSC) from umbilical blood containing natural killer cells, alloreactive on KIR-receptors of receptor-ligand type (NK-cells). Umbilical blood HSC transfusion is performed once with a fixed dose of leukocytes 40.0-60.0 × 10⁸ and NK-cells 4.0-6.0 × 10⁸ and three times with a fixed dose of leukocytes 20.0-30.0 × 10⁸ and NK-cells 1.4-3.0 × 10^8. Transfusion is preceded by a lymphodepleting chemotherapy based on cyclophosphamide in dose of 5 mg/kg; each transfusion is accompanied by the subcutaneous introduction of IL-2 in dose of 1 million units a day in amount of 5 such injections.

EFFECT: using the invention enables reducing the number of plasma cells, reducing the secretion of paraprotein IgG kappa in the patients with refractoriness with no side effects.

1 cl